九洲藥業(603456.SH):基本完成了製劑的全產業鏈佈局
格隆匯8月17日丨九洲藥業(603456.SH)近期在接待機構投資者調研時表示,幾年公司通過收購南京康川濟醫藥、山德士中山製劑工廠,同時自建四維醫藥製劑工廠等,基本完成了製劑的全產業鏈佈局,主要情況如下:
在創新藥製劑項目方面,中山製劑工廠已開始承接多個項目,其中也有來自海外的III期項目;在仿製藥製劑CRO業務方面,公司充分利用南京康川濟醫藥仿製藥一致性評價能力,以及中山製劑工廠中試和商業化生產能力,加快仿製藥CRO業務的承接;在傳統仿製製劑業務方面,公司取得了卡馬西平緩釋片、格列齊特緩釋片等多個製劑批件,並通過上藥九洲平台,持續推進特色原料藥製劑一體化業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.